Stock Hero Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

BHRT RSS Feed
Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Pierrocks, Gaintrader
Search This Board:
Last Post: 4/25/2015 12:24:31 PM - Followers: 173 - Board type: Free - Posts Today: 0

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

MyoCell 

MyoCell SDF-1 


MyoCath


AdipoCell

Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  

 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

**Important: Mike Tomás' personal StemCellCEO blog!**
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
    
BHRT - Daily Candlesticks

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BHRT
Current Price
Volume:
Bid Ask Day's Range
Wiki
BHRT News: Amended Statement of Ownership (sc 13g/a) 04/08/2015 10:04:05 AM
BHRT News: Annual Report (10-k) 03/16/2015 09:06:59 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:02:11 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:41 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:41 PM
PostSubject
#14846  Sticky Note Sunrise, FL – April 15, 2015 – Bioheart, Gaintrader 04/17/15 11:44:05 AM
#14995   So, that doesn't help us much further. ruke 04/24/15 04:43:51 PM
#14993   Revenues up 25% per CC stock down 20% Gsdubb 04/24/15 02:28:54 PM
#14992   There's nothing the matter with Bioheart. The stock Gsdubb 04/24/15 02:21:15 PM
#14991   What perspectives and questions on this afternoon's cc ruke 04/24/15 01:56:30 PM
#14989   Bid just dropped back into the .006's, holy Captain Kirk 04/24/15 01:22:53 PM
#14988   This sounds like corporate bullying to me. EquityElite 04/24/15 01:18:09 PM
#14987   Quote what? "Relatively there hasn't been that much Captain Kirk 04/24/15 01:10:33 PM
#14986   Dude every time there is good news the Gsdubb 04/24/15 12:28:36 PM
#14985   $1,100 bucks worth left at .007 on the Captain Kirk 04/24/15 12:23:30 PM
#14984   LOL quote, "The Value of One Cent! "?? Captain Kirk 04/24/15 12:16:26 PM
#14983   I didn't get a chance to hear the EquityElite 04/24/15 12:03:50 PM
#14982   All in due time$$$ Pierrocks 04/24/15 11:46:14 AM
#14981   The Value of One Cent! http://investorstemcell.com/company-news/the-value-of-on EquityElite 04/24/15 11:39:52 AM
#14978   50% increase is biohearts goal according to Mike andyshow 04/24/15 10:26:05 AM
#14977   LOL quote, "What is the expected revenues for 2015?" Captain Kirk 04/24/15 10:25:24 AM
#14976   This must be the "big conference call effect, Captain Kirk 04/24/15 10:02:27 AM
#14975   What is the expected revenues for 2015? EquityElite 04/24/15 09:51:00 AM
#14974   I'm not here for a mere 30 or pepemartinez 04/24/15 08:30:52 AM
#14973   Gsdubb someday BHRT will explode pepemartinez 04/24/15 07:53:16 AM
#14972   And this is just the beginning. The business Gsdubb 04/24/15 07:02:09 AM
#14971   Let's be a little realistic here. We all Gsdubb 04/24/15 07:00:56 AM
#14970   Equity, the cc was highly unimpressive imo. I dbates77 04/24/15 06:42:59 AM
#14969   accumulating when I can pepemartinez 04/24/15 06:04:12 AM
#14968   I expect a PR summarizing the material IMO. andyshow 04/24/15 12:21:27 AM
#14967   How was the CC? I missed it, was EquityElite 04/23/15 10:49:09 PM
#14965   Haven't lost anything. Just accumulating. Am I a Gsdubb 04/23/15 07:59:02 PM
#14964   How much has everyone lost on this pump toddski 04/23/15 07:54:22 PM
#14963   It was a great call. Those who fail andyshow 04/23/15 07:31:42 PM
#14962   Captain, I so want to believe in Bioheart. dbates77 04/23/15 05:52:46 PM
#14960   dbates, it was actually 7 1/2 minutes long, Captain Kirk 04/23/15 05:06:48 PM
#14959   The call kept breaking up for me. They Gsdubb 04/23/15 04:58:57 PM
#14958   James T., You were not so far off dbates77 04/23/15 04:55:01 PM
#14957   Where's the news? Ilcsm 04/23/15 04:48:23 PM
#14956   CC time TheTradingNinja 04/23/15 04:43:31 PM
#14955   Someone post the news its 430!! Ilcsm 04/23/15 04:29:38 PM
#14954   Nice close:) Tomorrow will be EXCITING$$$-Pier. Pierrocks 04/23/15 04:19:10 PM
#14953   dbates77, "conference call", blah, doesn't "do it" for Captain Kirk 04/23/15 03:47:00 PM
#14952   Last half our to load up!! 1 hour andyshow 04/23/15 03:30:22 PM
#14951   Time to Rock folks$$$-Pier. Pierrocks 04/23/15 03:28:28 PM
#14950   LOAD THE SHIP! IMO EquityElite 04/23/15 03:26:41 PM
#14947   Let's go bioheart!!! Great news coming IMO!! andyshow 04/23/15 02:03:56 PM
#14946   Captain James T. Kirk, I hope to hear dbates77 04/23/15 01:17:13 PM
#14945   LOL, quote "Conference Call today!! " Captain Kirk 04/23/15 12:28:02 PM
#14944   Conference Call today!! Red Cloud 04/23/15 12:15:26 PM
#14943   Quote LOL, "Bhrt is selling for a 109000% Captain Kirk 04/23/15 11:50:54 AM
#14942   BMAK sitting on the Ask w/ 10K share Captain Kirk 04/23/15 09:57:15 AM
#14941   Last chance to get in cheap:)IMO$$$ Pierrocks 04/23/15 09:35:57 AM
#14940   VERY calm and quiet today:) Good morning to slam4202 04/23/15 09:26:47 AM
#14939   Morning TheTradingNinja 04/23/15 08:04:15 AM
#14938   Good Morrning!!!Ready to Rock and Roll$$$ -Pier. Pierrocks 04/23/15 04:43:39 AM
PostSubject